21 related articles for article (PubMed ID: 11642327)
1. Correction to "Janus ACSP Nanoparticle for Synergistic Chemodynamic Therapy and Radiosensitization".
Xu M; Qian Y; Li X; Gu B; He S; Lu X; Song S
ACS Appl Mater Interfaces; 2024 Jun; ():. PubMed ID: 38838172
[No Abstract] [Full Text] [Related]
2. Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine.
Hou ZD; Xiao ZY; Gong Y; Zhang YP; Zeng QY
BMC Pharmacol Toxicol; 2014 Nov; 15():64. PubMed ID: 25413361
[TBL] [Abstract][Full Text] [Related]
3. The anthelmintic triclabendazole and its metabolites inhibit the membrane transporter ABCG2/BCRP.
Barrera B; Otero JA; Egido E; Prieto JG; Seelig A; Álvarez AI; Merino G
Antimicrob Agents Chemother; 2012 Jul; 56(7):3535-43. PubMed ID: 22508302
[TBL] [Abstract][Full Text] [Related]
4. Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans.
Buchwald P; Juhász A; Bell C; Pátfalusi M; Howes J; Bodor N
J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):377-400. PubMed ID: 16320099
[TBL] [Abstract][Full Text] [Related]
5. N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.
Kumagai S; Komada F; Kita T; Morinobu A; Ozaki S; Ishida H; Sano H; Matsubara T; Okumura K
Pharm Res; 2004 Feb; 21(2):324-9. PubMed ID: 15032315
[TBL] [Abstract][Full Text] [Related]
6. N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events.
Tanigawara Y; Kita T; Aoyama N; Gobara M; Komada F; Sakai T; Kasuga M; Hatanaka H; Sakaeda T; Okumura K
Biol Pharm Bull; 2002 Aug; 25(8):1058-62. PubMed ID: 12186410
[TBL] [Abstract][Full Text] [Related]
7. Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population.
Ma JJ; Liu CG; Li JH; Cao XM; Sun SL; Yao X
Clin Chim Acta; 2009 Sep; 407(1-2):30-5. PubMed ID: 19560446
[TBL] [Abstract][Full Text] [Related]
8. Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine.
Yokogawa K; Nakaharu T; Ishizaki J; Ozaki E; Takeda Y; Mabuchi H; Matsushita R; Kimura K; Nakashima E; Ichimura F; Miyamoto K
Int J Pharm; 2001 Oct; 229(1-2):183-91. PubMed ID: 11604271
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
Yamasaki Y; Ieiri I; Kusuhara H; Sasaki T; Kimura M; Tabuchi H; Ando Y; Irie S; Ware J; Nakai Y; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2008 Jul; 84(1):95-103. PubMed ID: 18167504
[TBL] [Abstract][Full Text] [Related]
10. N-Acetyltransferase 2 genotype correlates with sulfasalazine pharmacokinetics after multiple dosing in healthy Japanese subjects.
Kita T; Sakaeda T; Adachi S; Sakai T; Aoyama N; Hatanaka H; Kasuga M; Okumura K
Biol Pharm Bull; 2001 Oct; 24(10):1176-80. PubMed ID: 11642327
[TBL] [Abstract][Full Text] [Related]
11. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
